Diabetes I & II Stem Cell

DIABETES

Diabetes Types I and II patients are candidates for stem cell transplants. This would include patients that are on insulin daily injections; those that may be on a insulin pump; those that are on simply diet, exercise and oral hypoglycemic medication.

StemCellRegenMed reviews the patient’s past medical history; all laboratory tests including past month’s glucose monitoring, HgA1C, fasting insulin level; cholesterol, HDL, LDL, triglycerides; doses of insulin taken over the past two months. Details regarding blood pressure, heart disease, peripheral vascular disease, kidney problems, pulmonary, liver, eye status of retina, cornea, macula ;neuropathies should be included in the medical records sent to the company.

It is also desirable to determine if the patient has autoimmune diabetes by diagnostic evaluation of the immune system. If there are questions regarding this please contact the company’s physicians so that we can recommend laboratory tests to be done in advance of our treatment.

The protocol for treatment will include intravenous pancreatic stem cells extracted from umbilical cord blood that secrete insulin and agents that stimulate beta islet cell differentiation. Patients will be followed monthly after treatment at our clinic office in the U.S.A. and/or by telemedicine webcam conferences.

Follow-up laboratory tests will include glucose monitoring, HgA1C, fasting insulin, C Peptide studies. Oral natural agents will be added post stem cell procedure to assist in glycemic control.


		DIABETES Diabetes Types I and II patients are candidates for stem cell transplants. This would include patients that are on insulin daily injections; those that may be on a insulin pump; those that are on simply diet, exercise and oral hypoglycemic medication. StemCellRegenMed reviews the patient’s past medical history; all laboratory tests including past month’s glucose monitoring, HgA1C, fasting insulin level; cholesterol, HDL, LDL, triglycerides; doses of insulin taken over the past two months. Details regarding blood pressure, heart disease, peripheral vascular disease, kidney problems, pulmonary, liver, eye status of retina, cornea, macula ;neuropathies should be included in the medical records sent to the company. It is also desirable to determine if the patient has autoimmune diabetes by diagnostic evaluation of the immune system. If there are questions regarding this please contact the company’s physicians so that we can recommend laboratory tests to be done in advance of our treatment. The protocol for treatment will include intravenous pancreatic stem cells extracted from umbilical cord blood that secrete insulin and agents that stimulate beta islet cell differentiation. Patients will be followed monthly after treatment at our clinic office in the U.S.A. and/or by telemedicine webcam conferences. Follow-up laboratory tests will include glucose monitoring, HgA1C, fasting insulin, C Peptide studies. Oral natural agents will be added post stem cell procedure to assist in glycemic control.